Ligand Pharmaceuticals Incorporated
Bear Case (25th pct.)
-65.4% vs price
Base Case (Median)
-59.9% vs price
Bull Case (75th pct.)
-54.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $128.87 | -55.8% | High (40%) |
| PE Comparable | $208.08 | -28.7% | Medium (25%) |
| Graham Number | $105.20 | -63.9% | Medium (40%) |
| EV/EBITDA | $99.67 | -65.8% | Medium (20%) |
| EV/FCF | $135.86 | -53.4% | Medium (20%) |
| Earnings Power Value | $28.76 | -90.1% | Medium (50%) |
Based on 6 out of 8 methods, LGND appears overvalued at the current price of $291.77. The base case fair value of $117.03 implies 59.9% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.